BGE-102 advances in Phase II for CV and retinal diseases
BIOA says its NLRP3 inhibitor BGE-102 is advancing in Phase II for cardiovascular and retinal diseases, with key efficacy data expected next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.